Drug profile · INN
ruxolitinib phosphate
JAKAFI XR
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
ruxolitinib phosphate (JAKAFI XR) is an FDA-listed pharmaceutical active ingredient. Route of administration: topical. Current US regulatory status: approved.
Key facts
INN ruxolitinib phosphate
Brand JAKAFI XR
Route TOPICAL
Formulation TABLET
Frequently asked questions
What is ruxolitinib phosphate?
ruxolitinib phosphate (JAKAFI XR) is an FDA-listed pharmaceutical active ingredient. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for ruxolitinib phosphate?
JAKAFI XR is a marketed brand name for ruxolitinib phosphate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ruxolitinib phosphate?
ruxolitinib phosphate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.